Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICC APL Study 02 in pediatric acute promyelocytic leukemia
NL-OMON61093Phase 2Active, not recruiting
- Sponsor
- Italian Association of Pediatric Hematology and Oncology
- Start
- Dec 2024
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of arsenic trioxide, tretinoin and gemtuzumab ozogamicin in Acute promyelocytic leukaemia (APL) (2 arms), sponsored by Italian Association of Pediatric Hematology and Oncology. Primary endpoint: Event-free survival. Started Dec 2024; status: active, not recruiting.
02
Drugs
arsenic trioxidetretinoingemtuzumab ozogamicin
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on NL-OMON61093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61093.